Capsugel Showcases High-Quality Dosage Forms, Bioavailability Enhancement Technologies at Pharmtech Russia

November 25, 2013

Moscow, RUSSIA, Nov. 25, 2013Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry, announced its participation at the 15th annual Pharmtech exhibition in Moscow, Russia. Pharmtech, which runs from Nov. 25 – 28, is the top pharmaceutical industry-related trade event in Russia. Capsugel brings a wide range of solutions to the region, including its hard gelatin, liquid-filled and vegetarian capsules, as well as its bioavailability enhancement technologies and modified and targeted release capabilities.

“We have had an active presence in Russia for more than a decade, serving both domestic and international customers,” said Serge Enokian, Senior Vice President of Sales. “With the implementation of the ‘Pharma 2020’ plan, there is a shift toward greater domestic production of pharmaceutical products and investments in high-quality production capability that is compliant with international Good Manufacturing Practices (GMP) standards. Coupled with our own research showing consumer demand for convenient, innovative dosage forms in over-the-counter and nutritional products, there are significant opportunities in the Russian market.”

“Pharmtech provides an important venue to meet with customers and share our products and technologies that will help accelerate development and shorten timelines from concept to market,” added Serge.

During the event this week, Capsugel will feature its Vcaps® Plus HPMC capsule, Licaps® liquid-filled capsules, and the easy-to-open Coni-Snap® sprinkle capsules, which are expected to be available in 2014 on the Russian market. Capsugel will also debut its new Dosage Form Solutions (DFS) business, which offers a premier suite of bioavailability enhancement technologies, a full range of modified and targeted release technologies and specialized capabilities in several key areas, such as abuse deterrence, to solve customers’ most pressing drug development challenges. The Capsugel DFS model focuses on finished dosage forms, advancing client compounds from concept through clinical development to commercial supply.

“Capsugel’s presence at Pharmtech reinforces the company’s commitment to delivering high-quality products and technologies to Russia’s fast-growing pharmaceutical market,” added Koen Goosens, Capsugel’s Sales Manager for Eastern Europe. “We employ the principles of Six Sigma throughout our entire process to ensure customers receive the best quality products.”

During Pharmtech, visit Capsugel at stand D112 to learn more about its innovative portfolio of products and technologies.

Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit or